4:03 PM ET
8-K
Clinical Trial Data
Fennec Pharmaceuticals Clinical Trial Data
Fennec Pharmaceuticals announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK in Japan for pediatric and AYA patients. The study met its primary endpoint, showing hearing loss in only 24.0% of patients compared to a historical benchmark of 56.4%, while demonstrating no interference with cisplatin antitumor activity.